Promus Capital, LLC Sarepta Therapeutics, Inc. Transaction History
Promus Capital, LLC
- $113 Billion
- Q2 2025
A detailed history of Promus Capital, LLC transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Promus Capital, LLC holds 276 shares of SRPT stock, worth $6,748. This represents 0.0% of its overall portfolio holdings.
Number of Shares
276Holding current value
$6,748% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding SRPT
# of Institutions
452Shares Held
82MCall Options Held
5.61MPut Options Held
4.17M-
Black Rock Inc. New York, NY10.3MShares$252 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.16MShares$224 Million0.0% of portfolio
-
State Street Corp Boston, MA4.7MShares$115 Million0.0% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY4.48MShares$110 Million0.06% of portfolio
-
Wellington Management Group LLP Boston, MA2.53MShares$61.9 Million0.01% of portfolio
About Sarepta Therapeutics, Inc.
- Ticker SRPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 87,567,904
- Market Cap $2.14B
- Description
- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...